REGULATORY

Re-Pricing to Hit 23 Drugs in April; Takecab, GLP-1s, Vyndaqel/Vynmac, and More

January 19, 2022

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

A total of 23 drugs (APIs)/41 products will see their prices pared by special re-pricing rules in the FY2022 price revision in April, including Takeda Pharmaceutical’s acid reducer Takecab (vonoprazan) and all GLP-1 agents in injectable forms. A roster of…

To read the full story

Takecab Faces 15.8% Slash, GLP-1s 11.1% in FY2022 Drug Price Revision
March 4, 2022
Takecab Faces 2nd “Huge-Seller” Price Slash, All GLP-1 Injectables to Get Cut Too on Market Expansion
January 18, 2022

REGULATORY

LDP, Ishin Still at Odds on Social Security Reform; Pharma Role in Chuikyo Gains Traction
June 19, 2026
MHLW Panel OKs Technical Review Group for OTC-Like Drug Charge System
June 19, 2026
MHLW Official Warns of High Risks from GLP-1 Use in Cosmetic Weight Loss
June 19, 2026
LDP to Launch Study Group on Lag and Loss of Pediatric Cancer Drugs
June 19, 2026
LDP Patch League Urges Drug Price Support as Costs Continue to Climb
June 19, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…